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Abstract
The counter-regulatory axis of the renin angiotensin system peptide angiotensin-(1-7) [Ang-(1-7)] has been identified as a
potential therapeutic target in cardiac remodelling, acting via the mas receptor. Furthermore, we recently reported that an
alternative peptide, Ang-(1-9) also counteracts cardiac remodelling via the angiotensin type 2 receptor (AT2R). Here, we
have engineered adenoviral vectors expressing fusion proteins which release Ang-(1-7) [RAdAng-(1-7)] or Ang-(1-9)
[RAdAng-(1-9)] and compared their effects on cardiomyocyte hypertrophy in rat H9c2 cardiomyocytes or primary adult
rabbit cardiomyocytes, stimulated with angiotensin II, isoproterenol or arg-vasopressin. RAdAng-(1-7) and RAdAng-(1-9)
efficiently transduced cardiomyocytes, expressed fusion proteins and secreted peptides, as demonstrated by western
immunoblotting and conditioned media assays. Furthermore, secreted Ang-(1-7) and Ang-(1-9) inhibited cardiomyocyte
hypertrophy (Control = 168.768.4 mm; AngII = 232.1610.7 mm; AngII+RAdAng-(1-7) = 18669.1 mm, RAdAng-(1-
9) = 180.569 mm; P,0.05) and these effects were selectively reversed by inhibitors of their cognate receptors, the mas
antagonist A779 for RAdAng-(1-7) and the AT2R antagonist PD123,319 for RAdAng-(1-9). Thus gene transfer of Ang-(1-7) and
Ang-(1-9) produces receptor-specific effects equivalent to those observed with addition of exogenous peptides. These data
highlight that Ang-(1-7) and Ang-(1-9) can be expressed via gene transfer and inhibit cardiomyocyte hypertrophy via their
respective receptors. This supports applications for this approach for sustained peptide delivery to study molecular effects
and potential gene therapeutic actions.
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Introduction
The renin-angiotensin system (RAS) is recognized for its
systemic actions, however the presence of RAS components in
specific tissues (e.g. heart, brain, kidney), suggests the presence of a
local RAS. Furthermore, a counter-regulatory axis of the RAS
exists, which functions mainly via angiotensin converting enzyme
2 (ACE2)/angiotensin (Ang)-(1-7)/mas and inhibits many detri-
mental cardiovascular disease phenotypes [1,2]. Ang-(1-7) has
been shown to antagonise pathological actions such as cardiac
hypertrophy and fibrosis through the receptor mas [1,3]. Most
recently we reported that Ang-(1-9), a poorly characterised peptide
not previously reported as a receptor agonist, also had anti-
hypertrophic effects on angiotensin II (AngII)-induced cardiomy-
ocyte hypertrophy, as a functional ligand at the angiotensin type 2
receptor (AT2R) [4]. Moreover, we also demonstrated that Ang-(1-
9) reduced cardiac fibrosis in stroke prone spontaneously
hypertensive rats through the AT2R [5]. These studies highlight
the potential for therapeutic application of Ang-(1-7) and Ang-(1-9)
in cardiovascular disease applications. Though active angiotensin
peptides are generated extracellularly in the plasma via renin
mediated cleavage of angiotensinogen to angiotensin I, followed by
ACE-mediated cleavage to AngII, methods which enable their
expression through gene transfer approaches are available.
Transgenic expression of AngII and Ang-(1-7) can be mediated
through the use of synthetic fusion protein expression cassettes
which are expressed intracellularly and result in cleavage and
secretion of active peptides. Such approaches have been utilised to
demonstrate organ-specific effects of individual angiotensin
peptides in the heart, kidney and brain [6–14]. Gene therapy
approaches have also been reported for Ang-(1-7) in models of
both myocardial infarction and diabetic retinopathy using viral
vector-mediated gene transfer, highlighting their potential in this
setting [15,16]. Here, we have generated adenoviral (Ad) vectors
encoding fusion proteins expressing Ang-(1-7) or Ang-(1-9) and
compared their effects in models of cardiomyocyte hypertrophy.
We report that adenoviral gene transfer can be used to express
different angiotensin peptides and it can be shown that these
peptides are secreted from cells and maintain the receptor-specific
interactions that have been reported for the endogenous peptides.
This highlights the general applicability of this approach and
importantly for the first time demonstrates that Ang-(1-9) can be
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expressed via adenoviral gene transfer and mediate functional
effects at the AT2R.
Results
Generation of RAdAng-(1-7) and RAdAng-(1-9)
The fusion protein expression cassette consists of a signal
peptide, an IgG molecule linked to Ang-(1-7) or Ang-(1-9) and a
cleavage site for furin protease enabling active peptides to be
secreted (Figure 1A). Western immunoblotting of Ad transduced
H9c2 cardiomyocytes demonstrated expression of each fusion
protein with a size of 32 kDa as expected (Figure 1B).
Assessment of the Effects of RAdAng-(1-7) and RAdAng-
(1-9) Delivery on Cardiomyocyte Hypertrophy
First we assessed the efficiency of Ad transduction into H9c2 and
rabbit primary cardiomyocytes using a reporter gene (b-galactosi-
dase) expressing Ad vector. Doses of 500 and 1000 pfu/cell in H9c2
cells and 50 and 100 pfu/cell in rabbit cardiomoytes produced
approximately 50 and a 100% transduction, respectively (data not
shown). To assess the effects of RAdAng-(1-7) and RAdAng-(1-9) on
cardiomyocyte hypertrophyweused in vitro stimulationwithAngII as
described previously [4,17,18]. AngII induced cardiomyocyte
hypertrophy as expected (Figure 1C). Adenoviral gene delivery per
se did not affect cell size as RAd60 transduced cells were not
significantly different to AngII stimulated cells. However, at 500 and
1000 pfu/cell both RAdAng-(1-7) and RAdAng-(1-9) inhibited
AngII-induced hypertrophy (AngII = 232.1610.7 mm;RAdAng-(1-
7) 300 pfu= 209.2610.4 mm; RAdAng-(1-7)
500 pfu = 18669.1 mm; RAdAng-(1-7) 1000 pfu = 189.567.5 mm;
RAdAng-(1-9) 300 pfu = 191.4610.7 mm; RAdAng-(1-9)
500 pfu = 180.569.0 mm; RAdAng-(1-9)
1000 pfu = 178.569.1 mm; p,0.05), indicating that each RAd was
functional and antagonized AngII-induced hypertrophy. Next,
RAdAng-(1-7) and RAdAng-(1-9) were assessed in adult rabbit left
ventricular primary cardiomyocytes. Similarly to what was observed
previouslywithexogenouspeptides[4],RAdAng-(1-7)andRAdAng-
(1-9) were able to inhibit AngII-induced hypertrophy by preventing
the AngII-stimulated increase in cell width which is indicative of
concentric hypertrophic growth (Figure 1D).
Assessment of Peptide Secretion and Function from
RAdAng-(1-7) and RAdAng-(1-9) Transduced Cells
To demonstrate that Ang-(1-7) and Ang-(1-9) were secreted
from the cells in an active form a conditioned media assay was
utilised. HeLa cells were transduced with 100 pfu/cell of either
RAdAng-(1-7), RAdAng-(1-9) or RAd60 and incubated in serum
free media for 48 hours. Conditioned media was then transferred
to AngII-stimulated H9c2 cardiomyocytes (Figure 1E). Transfer of
conditioned media from RAd60 transduced HeLa cells to AngII-
stimulated H9c2 cardiomyocytes had no effect on hypertrophy.
However, transfer of conditioned media from RAdAng-(1-7) or
RAdAng-(1-9) transduced HeLa cells to AngII-stimulated cardio-
myocytes inhibited hypertrophy (p,0.01), thus confirming each
RAd expressed the fusion protein and secreted the active peptide
and produced effects equivalent to those observed previously with
direct peptide incubation [4]. To demonstrate that the peptides
expressed and secreted via gene transfer functioned similarly to
exogenous peptides, antagonists of mas and AT2R function were
assessed. In similarity to observations with exogenous peptides
[3,4], addition of A779 abolished the anti-hypertrophic effect of
RAdAng-(1-7), while RAdAng-(1-9) was able to inhibit AngII-
induced hypertrophy in the presence of A779 (Figure 2A).
Addition of PD123,319 did not block the antihypertrophic effect
of Ang-(1-7), but, completely eliminated those of RAdAng-(1-9)
(Figure 2B).
Assessment of RAdAng-(1-7) and RAdAng-(1-9) in
Cardiomyocyte Hypertrophy Induced with Different
Stimuli
To provide evidence that the antihypertrophic effects of
RAdAng-(1-7) or RAdAng-(1-9) delivery were not confined to
AngII stimulation, effects in cardiomyocyte hypertrophy induced
by isoproterenol and arg-vasopressin were measured (Figure 2C–
D). Both RAdAng-(1-7) and RAdAng-(1-9) were able to inhibit
isoproterenol and arg-vasopressin induced hypertrophy. This
verified that gene delivery of Ang-(1-7), or Ang-(1-9) was able to
inhibit cardiomyocyte hypertrophy induced with different stimuli
relevant to cardiovascular disease.
Discussion
We have generated adenoviral vectors which selectively over-
express Ang-(1-7) or Ang-(1-9). RAdAng-(1-7) and RAdAng-(1-9)
and transduce neonatal rat cardiomyoycte cell lines and adult
primary rabbit cardiomyocytes and secrete RAS peptides.
Transducing each respective cell type with viral vector doses
which achieved 50 or 100% transduction efficiency resulted in
secreted peptides inhibiting cardiomyocyte hypertrophy in the
same manner as described for exogenous peptides, via mas and
AT2R respectively [3,4], confirming over-expression and release of
active peptides via adenoviral transduction.
Currently, there is great interest in studying the counter-
regulatory ACE2/Ang-(1-7)/mas axis and our own recent
publications have also highlighted the importance of studying
other peptides such as Ang-(1-9), which may have, as yet, relatively
unexplored functions [4,5]. Most studies of angiotensin peptide
function utilise systemic delivery of peptides via osmotic mini-
pumps, however, transgenic models directing tissue-specific
production of angiotensin peptides to avoid confounding systemic
effects have also been developed [6–14]. These studies have
proved invaluable in our understanding of endogenous tissue-
specific RAS. However, the possibility of developmental abnor-
malities caused by embryonic over-expression following transgenic
model generation cannot be discounted. Such effects may explain
the discrepancies between transgenic studies and gene over-
expression studies. For example, ACE2 null mice have been
reported to have increased blood pressure with no cardiac changes
[2] while ACE2 overexpression by adeno-associated virus (AAV)
6-mediated gene delivery leads to severe cardiac fibrosis [19].
Furthermore, Ang-(1-7) has previously been investigated as a gene
therapeutic approach utilising viral vector mediated delivery. In a
rat model of myocardial ischaemia lentiviral gene transfer of Ang-
(1-7) 5 weeks before induction of myocardial infarction prevented
decreased myocardial performance as indicated by improvements
in fractional shortening and decreased myocardial wall thinning
[15]. In a model of diabetic retinopathy local ocular delivery of
adeno-associated virus (AAV) expressing Ang-(1-7) prevented
diabetes-induced retinal vascular damage and inflammation
[16]. Furthermore, adenoviral gene transfer of AngII to vascular
smooth muscle cells in vitro resulted in secretion of AngII and
functional effects on smooth muscle cell hypertrophy [20]. These
studies highlight the potential for gene transfer of angiotensin
peptides for molecular investigations and therapeutic approaches
and our study builds on these findings.
Adenoviral vectors mediate acute overexpression of genes in
adult cardiomyocytes in vitro and in vivo which may be applicable
for gene therapy applications in acute conditions such as
Gene Transfer of Ang-(1-7) and Ang-(1-9)
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Figure 1. Detection of fusion protein expression and functional assessment of RAdAng-(1-7) and RAdAng-(1-9). (A) Schematic of
fusion protein, consisting of a renin signal peptide to ensure secretion, murine IgG to provide mass for efficient production of the protein, a furin
protease cleavage domain (to invoke peptide release), and each peptide [6]. (B) H9c2 cardiomyocytes were transduced with 500 or 1000 pfu/cell of
RAdAng-(1-7), or RAdAng-(1-9), or RAd60 lysed after 48 h and subjected to electrophoresis. Fusion protein expression was detected by western
immunoblotting using a a-IgG2b antibody. kDa= kilodaltons. (C) H9c2 cardiomyocytes were transduced with RAdAng-(1-7), RAdAng-(1-9) or RAd60
at 500 and 1000 pfu/cell 24 h before AngII addition. Following 96 h incubation cells were fixed, stained with crystal violet and cell size measured.
*p,0.01 vs. unstimulated cells; #p,0.05 vs. AngII stimulated cells. (D) Freshly isolated left ventricular adult rabbit primary cardiomyocytes were
transduced with RAdAng-(1-7), RAdAng-(1-9) or RAd60 (50, 100 and 300 pfu/cell) 1 h before AngII (500 nM) addition. After 24 h cell width was
Gene Transfer of Ang-(1-7) and Ang-(1-9)
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measured. *p,0.01 vs. unstimulated cells; #p,0.01 vs. AngII stimulation. (E) HeLa cells were transduced with RAdAng-(1-7), RAdAng-(1-9) or RAd60
(100 pfu/cell) and incubated for 48 hours. Culture media from HeLa transduced cells (C.M; conditioned media) was transferred to H9c2
cardiomyocytes and incubated for 30 minutes before AngII (100 nM) addition. 96 hours later cells were fixed, stained with crystal violet and cell size
measured. *p,0.01 vs. unstimulated cells; #p,0.01 vs. AngII stimulated cells.
doi:10.1371/journal.pone.0045564.g001
Figure 2. Effect of Mas and AT2R antagonism on AngII-stimulated H9c2 cardiomyocyte hypertrophy following RAdAng-(1-7), or
RAdAng-(1-9) transduction. H9c2 cardiomyocytes were transduced with RAdAng-(1-7), RAdAng-(1-9) or RAd60 (negative control) +/2 (A) the Mas
antagonist A779 (10 mM) or (B) the AT2R antagonist PD123,319 (500 nM) 24 h before AngII addition. Cells were incubated for 96 h before fixing,
staining and measurement of cell size. *p,0.01 vs. unstimulated cells, #p,0.001 vs. AngII stimulated cells. H9c2 cardiomyocytes were transduced
with RAdAng-(1-7), RAdAng-(1-9) or RAd60 at 500 pfu/cell 24 h before addition of (C) 1 mM isoproterenol (Iso) or (D) 1 mM arg-vasopressin (vaso). Cell
size was measured at 96 h. *p,0.05 vs. unstimulated cells, #p,0.05 vs. isoproterenol or arg-vasopressin stimulated cells.
doi:10.1371/journal.pone.0045564.g002
Gene Transfer of Ang-(1-7) and Ang-(1-9)
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myocardial infarction (MI) and furthermore, their tropism is
efficient for other cell types in other organs such as kidney, brain
and skeletal muscle, which are also important to study tissue-
specific RAS effects. Moreover, for long term expression of
peptides in the heart AAV, particularly serotypes such as 1, 6 and
9 [21], can produce stable expression in myocardium following
non-invasive intravenous delivery which may be beneficial to
modulate long term detrimental remodelling in the heart following
an MI, in order to counter progression to heart failure. Therefore,
there are a range of delivery vectors which will enable assessment
of Ang-(1-7) and Ang-(1-9) in gene therapy approaches.
In summary, our data demonstrates that Ang-(1-7) and Ang-(1-
9) can be expressed via adenoviral gene transfer and inhibit
cardiomyocyte hypertrophy via their respective receptors. Future
work with these vectors is required in vivo to assess potential
therapeutic effects induced following cardiac-selective delivery.
Materials and Methods
Production of Recombinant Adenoviruses (RAd)
RAds expressing Ang-(1-7) [RAdAng-(1-7)] or Ang-(1-9) [RA-
dAng-(1-9)]were generated bymodifying pBluescript-pre-fc-proAn-
gII [22] (Figure 1A). The furin cleavage site and AngII encoding
nucleotideswereexcisedviaBglIIandEcoRIrestrictionandthevector
backbone gel purified. Oligonucleotides encoding a furin cleavage
site,Ang-(1-7) orAng-(1-9) flankedbyBglII andEcoRIrestriction sites
were commercially synthesised: Ang-(1-7) Forward 59-
GATCTCGCGTACGCACTAAACGCGACCGGGTGTACA-
TACACCCCTGAG-39, Reverse 39-AGCGCATGCGT-
GATTTGCGCTGGCCCACATGTATGTGGGGACTCT-
TAA-59; Ang-(1-9) Forward 59-
GATCTCGCGTACGCACTAAACGCGACCGGGTGTACA-
TACACCCCTTCC ACTGAG-39, Reverse 39-AGCG-
CATGCGTGATTTGCGCTGGCCCACATG-
TATGTGGGGA AGGTGACTCTTAA-59. Annealed
oligonucleotides encoding Ang-(1-7) or Ang-(1-9) were ligated into
pBluescript-pre-fc-pro and transformed into competentE.coli JM109
(Promega, Southampton, UK). Sequencing confirmed their correct
insertion. Next, Ang-(1-7) or Ang-(1-9) fusion protein encoding
expression cassettes were excised from pBluescript-pre-fc-pro,
purified and cloned into pVQ-CMV-KNpA and recombined with
pacAd5 9.2–100 in 293 cells [23] to generate RAdAng-(1-7) or
RAdAng-(1-9).RAd60 is a recombinantAdvectorwithout transgene
and has been described previously [24]. Adenoviral vectors were
amplified, purified and titered by standard protocols [25].
Cardiomyocyte Hypertrophy and Adenoviral
Transduction
H9c2 cardiomyocytes were obtained from ECACC (Wiltshire,
UK). The isolation of primary rabbit cardiomyocytes was
approved by the University of Glasgow Animal Procedures and
Ethics Committee and performed in strict accordance with UK
Home Office guidelines under the Animals Scientific Procedures
Act 1986. Isolation was performed as previously described [4].
Expression of the fusion proteins in H9c2 cardiomyocytes
transduced with 500 or 1000 plaque forming units (pfu)/cell of
each RAd for 48 h was confirmed by western immunoblotting as
described previously [22] using a mouse anti-IgG2b antibody
(rabbit polyclonal 1:250; Abcam, Cambridge, UK), which detects
expression of the IgG portion of the fusion protein (Figure 1A).
Cardiomyocytes were stimulated with AngII, arginine-vasopressin
or isoproterenol to induce hypertrophy as described previously
[4,17,18]. Cell size was measured using Image ProPlus 4.1 image
software (Media Cybernetics, Basingstoke, UK ). For each
condition we measured 100 cells (10 fields of view in each
condition). In H9c2 cardiomyocytes cell length was measured. In
primary cardiomyocytes midpoint width was measured as
previously described [4]. To assess RAdAng-(1-7) or RAd-(Ang-
1-9) in cardiomyocyte hypertrophy H9c2 cardiomyocytes were
transduced with 500 or 1000 plaque forming units (pfu)/cell and
primary rabbit left ventricular cardiomyocytes with 50, 100 or 300
pfu/cell of RAdAng-(1-7), RAdAng-(1-9) or RAd60 (negative
control). After 24 h incubation, cells were stimulated with AngII
(100 nM; Sigma, Dorset, UK), isoproterenol (1 mM; Sigma,
Dorset, UK) or arg-vasopressin (1 mM; Sigma, Dorset, UK) and
incubated for 96 hours (H9c2) or 24 h (rabbit). To assess receptor
use experiments were performed in the presence or absence of the
Mas antagonist A779 (10 mM; Bachem, Rhein, Germany) or the
AT2R antagonist PD123,319 (500 nM; Sigma, Dorset, UK).
Conditioned Media Assay
To provide evidence that the peptides were secreted using a
conditioned media assay. HeLa cells were transduced with
100 pfu/cell of either RAdAng1-7, RAdAng1-9 or RAd60 and
incubated in serum free media for 48 hours at 37uC to allow the
secreted peptides to accumulate in the media (conditioned media).
The conditioned media then was collected and added to previously
quiesced H9c2 cardiomyocytes 30 minutes before addition of
AngII (100 nM). H9c2 cardiomyocytes were incubated for 96
hours before measuring cell size as already mentioned.
Statistical Analysis
Experiments were performed in triplicate on 3 different
occasions. Mean 6 standard error of the mean (S.E.M) is
presented. One way ANOVA with Bonferroni’s correction for
multiple comparisons were applied and statistical difference was
considered with p values ,0.05.
Acknowledgments
We would like to thank Professor Timothy L Reudelhuber (University of
Montreal) for the kind gift of pBluescript-pre-fc-proAngII, Dr Tony
Workman and Ms Julie Russell (University of Glasgow) for the kind gift of
rabbit left ventricular tissue and Professor Beverley L Davidson (University
of Iowa) for the kind gift of pVQ-CMV-KNpA and pacAd5 9.2–100. We
thank Professor Andrew H. Baker for critical discussions regarding the
manuscript and Nicola Britton and Gregor Aitchison for technical
assistance.
Author Contributions
Conceived and designed the experiments: SAN. Performed the experi-
ments: MFM BMDCG AA. Analyzed the data: MFM BMDCG AA SAN.
Wrote the paper: SAN MFM.
References
1. Grobe JL, Mecca AP, Lingis M, Shenoy V, Bolton TA, et al. (2007) Prevention
of angiotensin II-induced cardiac remodeling by angiotensin-(1–7). Am J Physiol
Heart Circ Physiol 292: H736–742.
2. Gurley SB, Allred A, Le TH, Griffiths R, Mao L, et al. (2006) Altered blood
pressure responses and normal cardiac phenotype in ACE2-null mice. J Clin
Invest 116: 2218–2225.
3. Santos RA, Simoes e Silva AC, Maric C, Silva DM, Machado RP, et al. (2003)
Angiotensin-(1–7) is an endogenous ligand for the G protein-coupled receptor
Mas. Proc Natl Acad Sci U S A 100: 8258–8263.
4. Flores-Munoz M, Smith NJ, Haggerty C, Milligan G, Nicklin SA (2011)
Angiotensin1–9 antagonises pro-hypertrophic signalling in cardiomyocytes via
the angiotensin type 2 receptor. J Physiol 589: 939–951.
Gene Transfer of Ang-(1-7) and Ang-(1-9)
PLOS ONE | www.plosone.org 5 September 2012 | Volume 7 | Issue 9 | e45564
5. Flores-Munoz M, Work LM, Douglas K, Denby L, Dominiczak AF, et al. (2012)
Angiotensin-(1–9) attenuates cardiac fibrosis via the angiotensin type 2 receptor.
Hypertension 59: 300–307.
6. Ferreira AJ, Pinheiro SV, Castro CH, Silva GA, Silva AC, et al. (2006) Renal
function in transgenic rats expressing an angiotensin-(1–7)-producing fusion
protein. Regul Pept 137: 128–133.
7. Lochard N, Silversides DW, van Kats JP, Mercure C, Reudelhuber TL (2003)
Brain-specific restoration of angiotensin II corrects renal defects seen in
angiotensinogen-deficient mice. J Biol Chem 278: 2184–2189.
8. Mercure C, Yogi A, Callera GE, Aranha AB, Bader M, et al. (2008)
Angiotensin(1–7) blunts hypertensive cardiac remodeling by a direct effect on
the heart. Circ Res 103: 1319–1326.
9. Botelho-Santos GA, Sampaio WO, Reudelhuber TL, Bader M, Campagnole-
Santos MJ, et al. (2007) Expression of an angiotensin-(1–7)-producing fusion
protein in rats induced marked changes in regional vascular resistance.
Am J Physiol Heart Circ Physiol 292: H2485–2490.
10. Santos RA, Ferreira AJ, Nadu AP, Braga AN, de Almeida AP, et al. (2004)
Expression of an angiotensin-(1–7)-producing fusion protein produces cardio-
protective effects in rats. Physiol Genomics 17: 292–299.
11. van Kats JP, Methot D, Paradis P, Silversides DW, Reudelhuber TL (2001) Use
of a biological peptide pump to study chronic peptide hormone action in
transgenic mice. Direct and indirect effects of angiotensin II on the heart. J Biol
Chem 276: 44012–44017.
12. Nadu AP, Ferreira AJ, Reudelhuber TL, Bader M, Santos RA (2008) Reduced
isoproterenol-induced renin-angiotensin changes and extracellular matrix
deposition in hearts of TGR(A1–7)3292 rats. J Am Soc Hypertens 2: 341–348.
13. Santiago NM, Guimaraes PS, Sirvente RA, Oliveira LA, Irigoyen MC, et al.
(2010) Lifetime overproduction of circulating Angiotensin-(1–7) attenuates
deoxycorticosterone acetate-salt hypertension-induced cardiac dysfunction and
remodeling. Hypertension 55: 889–896.
14. Ferreira AJ, Castro CH, Guatimosim S, Almeida PW, Gomes ER, et al. (2010)
Attenuation of isoproterenol-induced cardiac fibrosis in transgenic rats
harboring an angiotensin-(1–7)-producing fusion protein in the heart. Ther
Adv Cardiovasc Dis.
15. Qi Y, Shenoy V, Wong F, Li H, Afzal A, et al. (2011) Lentiviral mediated
overexpression of Angiotensin-(1–7) attenuated ischemia-induced cardiac
pathophysiology. Exp Physiol.
16. Verma A, Shan Z, Lei B, Yuan L, Liu X, et al. (2011) ACE2 and Ang-(1–7)
Confer Protection Against Development of Diabetic Retinopathy. Mol Ther.
17. Zou Y, Komuro I, Yamazaki T, Kudoh S, Uozumi H, et al. (1999) Both Gs and
Gi proteins are critically involved in isoproterenol-induced cardiomyocyte
hypertrophy. J Biol Chem 274: 9760–9770.
18. Hiroyama M, Wang S, Aoyagi T, Oikawa R, Sanbe A, et al. (2007) Vasopressin
promotes cardiomyocyte hypertrophy via the vasopressin V1A receptor in
neonatal mice. Eur J Pharmacol 559: 89–97.
19. Masson R, Nicklin SA, Craig MA, McBride M, Gilday K, et al. (2009) Onset of
Experimental Severe Cardiac Fibrosis Is Mediated by Overexpression of
Angiotensin-Converting Enzyme 2. Hypertension.
20. Takayanagi T, Bourne AM, Kimura K, Takaguri A, Elliott KJ, et al. (2012)
Constitutive stimulation of vascular smooth muscle cells by angiotensin II
derived from an adenovirus encoding a furin-cleavable fusion protein.
Am J Hypertens 25: 280–283.
21. Palomeque J, Chemaly ER, Colosi P, Wellman JA, Zhou S, et al. (2007)
Efficiency of eight different AAV serotypes in transducing rat myocardium in
vivo. Gene Ther 14: 989–997.
22. Methot D, LaPointe MC, Touyz RM, Yang XP, Carretero OA, et al. (1997)
Tissue targeting of angiotensin peptides. J Biol Chem 272: 12994–12999.
23. Anderson RD, Haskell RE, Xia H, Roessler BJ, Davidson BL (2000) A simple
method for the rapid generation of recombinant adenovirus vectors. Gene Ther
7: 1034–1038.
24. George SJ, Wan S, Hu J, MacDonald R, Johnson JL, et al. (2011) Sustained
reduction of vein graft neointima formation by ex vivo TIMP-3 gene therapy.
Circulation 124: S135–142.
25. Nicklin SA, Baker AH (1999) Simple methods for preparing recombinant
adenoviruses for high efficiency transduction of vascular cells. In: Baker AH,
editor. Vascular Disease: Molecular Biology and Gene Therapy Protocols
(Methods in Molecular Medicine). New York: Humana Press. 271–283.
Gene Transfer of Ang-(1-7) and Ang-(1-9)
PLOS ONE | www.plosone.org 6 September 2012 | Volume 7 | Issue 9 | e45564
